Building Australia's
Medical Isotope Capability
The Team Behind IsoMedica
entX is bringing together specialist nuclear science, engineering and manufacturing expertise to develop a scalable medical isotope production platform through IsoMedica.

Turning complex nuclear science into commercially viable medical isotope production requires more than technical expertise. It takes the right people, infrastructure and industry partnerships to establish reliable, scalable production capabilities.
Led by Chief Scientific Officer Massey de los Reyes, IsoMedica brings together expertise across radiochemical processing, isotope supply chains, nuclear science, radiation safety, manufacturing engineering and automation.
This multidisciplinary approach is central to entX's goal of translating technical innovation into a commercially focused medical isotope platform.
From Science to Commercial Delivery
For entX, the focus extends beyond proving processes in a laboratory. It is about establishing an operational platform capable of delivering reliable medical isotope production and supply at scale. As global demand for medical isotopes grows, dependable production systems and secure supply chains will play an increasingly important role in supporting nuclear medicine and the development of advanced cancer treatments.
Through IsoMedica, entX is working to move from proof of concept towards proven, customer-driven production capability, combining scientific expertise, engineering and industry partnerships to support long-term commercial delivery.
Building for the Future of Nuclear Medicine
IsoMedica represents an important part of entX's broader strategy to develop and commercialise advanced nuclear technologies.
By bringing together the people, systems and expertise needed to support medical isotope production, entX is working to establish a platform designed to contribute to the future of nuclear medicine.
OTher Projects
